Breast Cancer Gene-Edited Cell Lines for Drug Discovery

Breast carcinoma is the most frequently diagnosed cancer among women worldwide, with approximately 2.3 million new cases and 685,000 deaths in 2020 (WHO, 2021). The 5-year relative survival rate for localized breast cancer is 99%, but drops to 31% for distant-stage disease (NCI SEER, 2023). Key risk factors include age, genetic predisposition (BRCA1/BRCA2 mutations), hormone exposure, and lifestyle factors. The disease accounts for 15% of all female cancer deaths globally.

Breast cancer is an ideal model for mechanistic studies due to its well-characterized molecular subtypes (Luminal A, Luminal B, HER2-enriched, Basal-like/TNBC), extensive public genomic datasets (TCGA, COSMIC), and established cell line panels. Open questions include mechanisms of endocrine therapy resistance, immune evasion in triple-negative breast cancer (TNBC), and synthetic lethal interactions with BRCA mutations.

• • Estrogen receptor (ER) signaling: ER-alpha activation drives proliferation in Luminal subtypes.
• • Steps: Estrogen binding -> ER dimerization -> nuclear translocation -> transcription of growth genes.
• • HER2/ErbB2 signaling: Amplification leads to constitutive activation of MAPK and PI3K/AKT pathways.
• • Steps: Receptor homodimerization -> GRB2/SOS recruitment -> RAS activation -> RAF/MEK/ERK cascade.
• • DNA damage repair deficiency: BRCA1/BRCA2 loss impairs homologous recombination repair (HRR), leading to genomic instability.
• • p53 pathway disruption: TP53 mutations abrogate cell cycle arrest and apoptosis, common in Basal-like tumors.

Data from TCGA (Nature, 2012) and COSMIC v99.

• • PI3K/AKT/mTOR pathway: Activated by PIK3CA mutations or PTEN loss; promotes cell growth and survival.
• • Key nodes: PI3K, AKT, mTOR, S6K, 4E-BP1.
• • RAS/MAPK pathway: Hyperactivated by HER2 amplification or KRAS mutations; drives proliferation.
• • Key nodes: KRAS, BRAF, MEK1/2, ERK1/2.
• • Wnt/beta-catenin pathway: Dysregulated in TNBC; promotes epithelial-mesenchymal transition (EMT).
• • Key nodes: beta-catenin, TCF/LEF, LRP5/6.
• • Notch signaling: Aberrant activation in breast cancer stem cells; regulates self-renewal.
• • Key nodes: Notch1-4, DLL1/4, JAG1/2, CSL.

Organoids derived from patient tumors retain heterogeneity and 3D architecture, enabling drug response testing and co-culture with immune cells.

• • Patient-derived xenografts (PDX): Implantation of fresh tumor fragments into immunodeficient mice; preserves tumor microenvironment and genetic diversity.
• • Example: TNBC PDX models with BRCA1 mutations.
• • Genetically engineered mouse models (GEMM): Conditional knockout of Brca1/Trp53 in mammary epithelium (K14-Cre; Brca1f/f; Trp53f/f).
• • Inducible models: MMTV-rtTA/TetO-HER2 mice for doxycycline-regulated HER2 expression.

• • CRISPR/Cas9 technology enables the generation of isogenic cell lines with precise genetic modifications, eliminating confounding background effects. Examples include:
• • TP53 knockout in MCF7 cells to study p53 loss-of-function.
• • KRAS G12D knock-in in MDA-MB-231 cells to model activating RAS mutations.
• • BRCA1 frameshift knock-in in HCC1937 to restore HRR function.

Commercially available, sequence-verified gene-edited cell models accelerate target validation and drug screening by providing reproducible, isogenic controls. These models are available from commercial sources as cryopreserved vials or genomic DNA.

• • Knockout and knock-in lines enable direct causal testing of candidate genes. For example:
• • PIK3CA H1047R knock-in in MCF10A cells induces transformation and AKT hyperactivation.
• • TP53 knockout in MCF7 cells increases genomic instability and resistance to DNA-damaging agents.
• • CDH1 knockout in MCF7 cells promotes EMT and invasive behavior.

• • Isogenic pairs (wild-type vs. mutant) are used to identify mutation-specific drug sensitivities. Examples:
• • PIK3CA mutant vs. wild-type isogenic lines for PI3K inhibitor screening.
• • BRCA1 knockout lines for PARP inhibitor sensitivity assays.
• • Resistance modeling: Chronic exposure of HER2-amplified cells to trastuzumab, followed by CRISPR knockout of candidate resistance genes (e.g., PTEN).

• • CRISPR synthetic lethality screens identify genes essential only in specific genetic backgrounds. For example:
• • BRCA1-deficient cells are synthetically lethal with PARP1 inhibition.
• • Genome-wide CRISPR screens in TP53-null cells revealed vulnerabilities in the G2/M checkpoint (e.g., WEE1).
• • Screens in HER2-amplified cells identified ERBB3 as a co-dependency.